SUBSCRIBE: Print / eNewsletter
Impact of SOFT/TEXT in Premenopausal Breast Cancer
This video reviews the impact of the SOFT/TEXT trials for the treatment of patients with premenopausal breast cancer, and ways to best use the results.
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer.
Using Molecular Tools to Guide Breast Cancer Treatment
This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer.
Tackling Endocrine Resistance in Breast Cancer
This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.
Chemotherapy Decision-Making in Early Breast Cancer
This video discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.
Planned Radiation in Axillary Management of Breast Cancer
This video examines how planned radiation will impact management of the axilla in breast cancer patients undergoing mastectomy.
Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets
This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.
Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
ASCO 2017: Updates on HER2-Positive Breast Cancer Treatment
This video highlights the latest studies presented at the 2017 ASCO Annual Meeting on the treatment of HER2-positive breast cancer.
Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.